Media coverage about Cerecor (NASDAQ:CERC) has been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cerecor earned a daily sentiment score of 0.11 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.381433395899 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Here are some of the news articles that may have impacted Accern’s analysis:

Cerecor (NASDAQ CERC) traded down 0.27% during trading on Friday, reaching $0.73. The company had a trading volume of 298,990 shares. The stock has a 50 day moving average price of $0.70 and a 200 day moving average price of $0.66. The firm’s market capitalization is $19.02 million. Cerecor has a 52 week low of $0.34 and a 52 week high of $5.60.

Cerecor (NASDAQ:CERC) last announced its quarterly earnings results on Monday, August 14th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.15. The company had revenue of $0.16 million for the quarter. Cerecor had a negative return on equity of 1,325.84% and a negative net margin of 1,106.99%. Analysts predict that Cerecor will post ($1.07) earnings per share for the current year.

In related news, major shareholder Armistice Capital Master Fund purchased 219,792 shares of the business’s stock in a transaction on Monday, August 21st. The shares were bought at an average cost of $0.60 per share, with a total value of $131,875.20. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have acquired a total of 1,487,062 shares of company stock worth $936,238 over the last ninety days. 10.70% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: “Cerecor (CERC) Receives News Impact Score of 0.11” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/09/02/cerecor-cerc-receives-news-impact-score-of-0-11.html.

Cerecor Company Profile

Cerecor, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.

Insider Buying and Selling by Quarter for Cerecor (NASDAQ:CERC)

Receive News & Stock Ratings for Cerecor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor Inc. and related stocks with our FREE daily email newsletter.